on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Releases H1 2025 Financial Report
Sartorius Stedim Biotech SA has announced the availability of its report on the first half of 2025 financial results. The document can be accessed through their investor relations webpage. It provides insights into the business development from January to June 2025, alongside forecasts for the full year.
The report includes consolidated financial statements for the period ending June 30, 2025. Sartorius Stedim Biotech, headquartered in Aubagne, France, is a significant player in the biopharmaceutical sector. The company supports the manufacturing of biotech drugs, including cell and gene therapies. In 2024, it achieved sales revenue of approximately 2.8 billion euros and employs over 9,900 people worldwide.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news